Regional trends and disparities in newer <scp>GLP1</scp> receptor agonist initiation among real‐world adult patients eligible for obesity treatment
The initiation of newer AOMs among overweight and obese populations remains low, but uptake has increased exponentially since 2022. Our findings reveal significant disparities in obesity care, highlighting the importance of addressing inequities in AOM access to improve obesity outcomes.
Authors
- Pareeta Kotecha (ORCID: https://orcid.org/0009-0009-4864-9662)
- Rotana M. Radwan (ORCID: https://orcid.org/0000-0003-0061-0637)
- John M. Allen (ORCID: https://orcid.org/0000-0002-0033-4508)
- William T. Donahoo (ORCID: https://orcid.org/0000-0002-2126-860X)
- Jiang Bian (ORCID: https://orcid.org/0000-0002-2238-5429)
- Yao An Lee (ORCID: https://orcid.org/0009-0008-3971-4242)
- Inmaculada Hernández (ORCID: https://orcid.org/0000-0002-9305-1442)
- Jingchuan Guo (ORCID: https://orcid.org/0000-0001-9799-2592)
- Davene R. Wright (ORCID: https://orcid.org/0000-0002-8574-4572)
- Yong Chen (ORCID: https://orcid.org/0000-0003-0835-0788)
- Ronald Ramon
Institutions
- Regenstrief Institute (US)
- Harvard University (US)
- University of Florida (US)
- Harvard Pilgrim Health Care (US)
- Indiana University Bloomington (US)
- Indiana University – Purdue University Indianapolis (US)
- University of Montana (US)
- University of Pennsylvania (US)
- Florida College (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1111/dom.16318
- Citations
- 10
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 12.95